Different profiles of circulating arginase 2 in subtypes of preeclampsia pregnant women

Hutcheon, 2011, Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy, Best Pract. Res. Clin. Obstet. Gynaecol., 10.1016/j.bpobgyn.2011.01.006 American College of Obstetricians, Task Force on Hypertension in Pregnancy, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, in: Obstet. Gynecol., 2013. https://doi.org/10.1097/01.AOG.0000437382.03963.88. Rana, 2019, Preeclampsia: pathophysiology, challenges, and perspectives, Circ. Res., 10.1161/CIRCRESAHA.118.313276 Sandrim, 2010, ENOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension, Pharmacogenomics J., 10.1038/tpj.2009.38 Amaral, 2017, Pathophysiology and current clinical management of preeclampsia, Curr. Hypertens. Rep., 10.1007/s11906-017-0757-7 Podymow, 2008, Update on the use of antihypertensive drugs in pregnancy, Hypertension, 51, 960, 10.1161/HYPERTENSIONAHA.106.075895 Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222, Obstet. Gynecol. (2020). https://doi.org/10.1097/AOG.0000000000003891. Roberts, 2005, Preeclampsia: recent insights, Hypertension, 10.1161/01.HYP.0000188408.49896.c5 Sandrim, 2008, Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia, Hypertension, 10.1161/HYPERTENSIONAHA.108.115006 Johal, 2014, The nitric oxide pathway and possible therapeutic options in pre-eclampsia, Br. J. Clin. Pharmacol., 10.1111/bcp.12301 Sankaralingam, 2010, Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia, Cardiovasc. Res., 10.1093/cvr/cvp277 Caldwell, 2015, Arginase: an old enzyme with new tricks, Trends Pharmacol. Sci., 10.1016/j.tips.2015.03.006 Berkowitz, 2003, Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels, Circulation, 10.1161/01.CIR.0000092948.04444.C7 White, 2006, Knockdown of arginase I restores NO signaling in the vasculature of old rats, Hypertension, 10.1161/01.HYP.0000198543.34502.d7 Kossel, 1904, Über die Arginase, Hoppe. Seylers, Z. Physiol. Chem., 10.1515/bchm2.1904.41.4.321 Ryoo, 2008, Endothelial arginase II: a novel target for the treatment of atherosclerosis, Circ. Res., 10.1161/CIRCRESAHA.107.169573 Xia, 1996, Nitric oxide synthase generates Superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury, Proc. Natl. Acad. Sci. U.S.A., 10.1073/pnas.93.13.6770 Ryoo, 2011, OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling, Atherosclerosis, 10.1016/j.atherosclerosis.2010.10.044 You, 2015, Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy, Am. J. Physiol. Bernardi, 2008, Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women, J. Obstet. Gynaecol. Res., 10.1111/j.1447-0756.2008.00860.x González-Garrido Chem, 2013, Influence of the at 2 receptor on the L-arginine-nitric oxide pathway and effects of (-)-epicatechin on HUVECs from women with preeclampsia, J. Hum. Hypertens., 10.1038/jhh.2012.55 Noris, 2004, L-Arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species, Hypertension, 10.1161/01.HYP.0000116220.39793.c9 Caldwell, 2018, Arginase: a multifaceted enzyme important in health and disease, Physiol. Rev., 10.1152/physrev.00037.2016 Romero, 2008, Diabetes-induced coronary vascular dysfunction involves increased arginase activity, Circ. Res., 10.1161/CIRCRESAHA.107.155028 Zhang, 2001, Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function, FASEB J., 10.1096/fj.00-0681fje Bagnost, 2009, Misregulation of the arginase pathway in tissues of spontaneously hypertensive rats, Hypertens. Res., 10.1038/hr.2009.153 Demougeot, 2007, Time course of vascular arginase expression and activity in spontaneously hypertensive rats, Life Sci., 10.1016/j.lfs.2006.12.003 Zhang, 2004, Upregulation of vascular arginase in hypertension decreases nitric oxide-mediated dilation of coronary arterioles, Hypertension, 10.1161/01.HYP.0000146907.82869.f2 Luizon, 2014, Tissue inhibitor of matrix metalloproteinase-1 polymorphism, plasma TIMP-1 levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy, Pharmacogenomics J., 10.1038/tpj.2014.26 Luizon, 2017, Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy, Pharmacogenomics J., 10.1038/tpj.2016.35 LaMarca, 2007, Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia, Curr. Hypertens. Rep. Kim, 2004, Maternal serum levels of VCAM-1, ICAM-1 and E-selectin in preeclampsia, J. Korean Med. Sci. Xu, 2012, Maternal plasma levels of endothelial dysfunction mediators including AM, CGRP, sICAM-1 and tHcy in pre-eclampsia, Adv. Clin. Exp. Med. Maynard, 2003, Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsia, J. Clin. Invest., 10.1172/JCI17189 Serdar, 2006, Serum iron and copper status and oxidative stress in severe and mild preeclampsia, Cell Biochem. Funct., 10.1002/cbf.1235 Can, 2011, Inflammatory markers in preeclamptic patients, Clin. Chem. Lab. Med., 10.1515/CCLM.2011.232 Pandey, 2014, Transcriptional regulation of endothelial arginase 2 by histone deacetylase 2, Arterioscler. Thromb. Vasc. Biol., 10.1161/ATVBAHA.114.303685 Tanaka, 2018, Arginase controls soluble vascular endothelial growth factor receptor 1 (sFlt1) to maintain pregnancy homeostasis, Biochem. Biophys. Res. Commun., 10.1016/j.bbrc.2018.03.086 Rios, 2016, Increased levels of sENG and sVCAM-1 and decreased levels of VEGF in severe preeclampsia, Am. J. Hypertens., 10.1093/ajh/hpv170 K.J. Peyton X. ming Liu, A.R. Shebib, F.K. Johnson, R.A. Johnson, W. Durante, Arginase inhibition prevents the development of hypertension and improves insulin resistance in obese rats, Amino Acids (2018). https://doi.org/10.1007/s00726-018-2567-x. Yepuri, 2012, Positive crosstalk between arginase-II and S6K1 in vascular endothelial inflammation and aging, Aging Cell, 10.1111/acel.12001 Sankaralingam, 2009, Evidence for increased methylglyoxal in the vasculature of women with preeclampsia: role in upregulation of LOX-1 and arginase, Hypertension, 10.1161/HYPERTENSIONAHA.109.135228 Possomato-Vieira, 2016, Mechanisms of endothelial dysfunction in hypertensive pregnancy and preeclampsia, Adv. Pharmacol., 10.1016/bs.apha.2016.04.008